| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 11 | 2024 | 254 | 3.590 |
Why?
|
| Hypertension, Pregnancy-Induced | 6 | 2021 | 74 | 2.360 |
Why?
|
| Activins | 4 | 2022 | 26 | 2.340 |
Why?
|
| Cardiomyopathies | 9 | 2024 | 263 | 2.190 |
Why?
|
| Patient Readmission | 4 | 2019 | 350 | 1.920 |
Why?
|
| Echocardiography | 13 | 2021 | 935 | 1.810 |
Why?
|
| Postpartum Period | 4 | 2024 | 143 | 1.650 |
Why?
|
| Ventricular Function, Left | 4 | 2022 | 602 | 1.610 |
Why?
|
| Heart Diseases | 5 | 2024 | 297 | 1.550 |
Why?
|
| Sepsis | 5 | 2018 | 317 | 1.510 |
Why?
|
| Pregnancy | 23 | 2024 | 2997 | 1.330 |
Why?
|
| Heart Ventricles | 4 | 2021 | 779 | 1.310 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2017 | 107 | 1.240 |
Why?
|
| Perioperative Care | 7 | 2022 | 169 | 1.200 |
Why?
|
| Blood Pressure | 4 | 2018 | 893 | 1.030 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 181 | 1.030 |
Why?
|
| Shock, Cardiogenic | 3 | 2018 | 104 | 1.010 |
Why?
|
| Anesthesiology | 8 | 2022 | 160 | 1.010 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2019 | 327 | 0.970 |
Why?
|
| Peripartum Period | 3 | 2024 | 29 | 0.900 |
Why?
|
| Biomedical Research | 2 | 2018 | 390 | 0.870 |
Why?
|
| Stroke Volume | 3 | 2022 | 460 | 0.860 |
Why?
|
| Critical Care | 4 | 2020 | 379 | 0.810 |
Why?
|
| Humans | 76 | 2024 | 88694 | 0.800 |
Why?
|
| Shock, Septic | 4 | 2018 | 104 | 0.790 |
Why?
|
| Retrospective Studies | 20 | 2024 | 8903 | 0.760 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2018 | 94 | 0.740 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1843 | 0.720 |
Why?
|
| Inpatients | 2 | 2020 | 308 | 0.710 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 165 | 0.710 |
Why?
|
| Prospective Studies | 16 | 2022 | 4272 | 0.700 |
Why?
|
| Prenatal Care | 1 | 2020 | 77 | 0.690 |
Why?
|
| Female | 39 | 2024 | 45812 | 0.690 |
Why?
|
| Myocardial Contraction | 1 | 2021 | 252 | 0.690 |
Why?
|
| Length of Stay | 4 | 2018 | 727 | 0.680 |
Why?
|
| Adult | 28 | 2024 | 26383 | 0.670 |
Why?
|
| Aspirin | 1 | 2020 | 159 | 0.660 |
Why?
|
| Palpation | 1 | 2018 | 18 | 0.660 |
Why?
|
| Critical Illness | 2 | 2019 | 305 | 0.650 |
Why?
|
| Biomarkers | 7 | 2021 | 1756 | 0.640 |
Why?
|
| Hypertension | 4 | 2024 | 733 | 0.630 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 159 | 0.630 |
Why?
|
| Publication Bias | 1 | 2017 | 13 | 0.600 |
Why?
|
| Fluid Therapy | 1 | 2018 | 51 | 0.600 |
Why?
|
| Pregnancy Complications | 3 | 2017 | 344 | 0.590 |
Why?
|
| Lung Injury | 1 | 2018 | 53 | 0.590 |
Why?
|
| Editorial Policies | 1 | 2017 | 34 | 0.580 |
Why?
|
| Endoglin | 1 | 2017 | 21 | 0.580 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 80 | 0.580 |
Why?
|
| Biostatistics | 1 | 2017 | 20 | 0.580 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 115 | 0.570 |
Why?
|
| Databases, Factual | 5 | 2018 | 846 | 0.560 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 250 | 0.560 |
Why?
|
| Blood Transfusion | 1 | 2017 | 164 | 0.560 |
Why?
|
| Hospital Mortality | 2 | 2018 | 381 | 0.550 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 431 | 0.540 |
Why?
|
| Angiogenic Proteins | 1 | 2016 | 17 | 0.540 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2015 | 516 | 0.530 |
Why?
|
| Young Adult | 11 | 2020 | 6232 | 0.530 |
Why?
|
| Pharmacogenomic Testing | 3 | 2021 | 98 | 0.510 |
Why?
|
| Pharmacogenetics | 5 | 2022 | 443 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 837 | 0.500 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 224 | 0.490 |
Why?
|
| Heart | 3 | 2017 | 572 | 0.490 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 37 | 0.480 |
Why?
|
| Pregnancy Outcome | 4 | 2018 | 253 | 0.480 |
Why?
|
| Research Design | 1 | 2018 | 594 | 0.470 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2018 | 346 | 0.470 |
Why?
|
| Risk Factors | 10 | 2021 | 5456 | 0.460 |
Why?
|
| Aortic Valve Stenosis | 2 | 2012 | 143 | 0.460 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 265 | 0.450 |
Why?
|
| Heart Failure | 2 | 2024 | 1172 | 0.450 |
Why?
|
| Hospitals | 2 | 2021 | 298 | 0.440 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 753 | 0.410 |
Why?
|
| Hospitalization | 2 | 2015 | 871 | 0.400 |
Why?
|
| Adolescent | 9 | 2018 | 9170 | 0.370 |
Why?
|
| Anesthesia | 3 | 2022 | 169 | 0.370 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1851 | 0.370 |
Why?
|
| Aged | 16 | 2019 | 18970 | 0.370 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 6740 | 0.370 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2018 | 473 | 0.350 |
Why?
|
| Cohort Studies | 6 | 2018 | 2837 | 0.340 |
Why?
|
| United States | 7 | 2019 | 6898 | 0.330 |
Why?
|
| Treatment Outcome | 8 | 2022 | 8187 | 0.330 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 995 | 0.320 |
Why?
|
| Image Enhancement | 1 | 2012 | 567 | 0.320 |
Why?
|
| Middle Aged | 14 | 2019 | 25742 | 0.320 |
Why?
|
| Operating Rooms | 2 | 2019 | 128 | 0.290 |
Why?
|
| Internship and Residency | 5 | 2019 | 1038 | 0.290 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2019 | 78 | 0.280 |
Why?
|
| Vasoconstrictor Agents | 2 | 2017 | 55 | 0.280 |
Why?
|
| Male | 20 | 2022 | 42059 | 0.280 |
Why?
|
| Time Factors | 3 | 2021 | 5320 | 0.280 |
Why?
|
| Logistic Models | 4 | 2017 | 1207 | 0.260 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1709 | 0.260 |
Why?
|
| Clinical Competence | 4 | 2016 | 780 | 0.260 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2011 | 191 | 0.250 |
Why?
|
| Intensive Care Units | 2 | 2019 | 389 | 0.250 |
Why?
|
| Curriculum | 3 | 2019 | 564 | 0.250 |
Why?
|
| Communication | 2 | 2019 | 452 | 0.240 |
Why?
|
| Labor, Obstetric | 2 | 2022 | 46 | 0.240 |
Why?
|
| Placenta | 2 | 2024 | 178 | 0.230 |
Why?
|
| Anesthetics, Inhalation | 1 | 2024 | 98 | 0.220 |
Why?
|
| Cesarean Section | 3 | 2018 | 140 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2024 | 84 | 0.220 |
Why?
|
| Sex Work | 1 | 2002 | 12 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2020 | 2286 | 0.220 |
Why?
|
| Preoperative Care | 2 | 2017 | 398 | 0.210 |
Why?
|
| Prognosis | 4 | 2021 | 3753 | 0.210 |
Why?
|
| Monitoring, Intraoperative | 3 | 2018 | 110 | 0.210 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.200 |
Why?
|
| Analgesia, Obstetrical | 1 | 2022 | 21 | 0.200 |
Why?
|
| Postnatal Care | 2 | 2021 | 27 | 0.200 |
Why?
|
| Analgesia, Epidural | 1 | 2022 | 38 | 0.200 |
Why?
|
| Breast Feeding | 2 | 2002 | 98 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 3658 | 0.200 |
Why?
|
| Mitral Valve | 3 | 2012 | 260 | 0.200 |
Why?
|
| Respiratory System | 1 | 2022 | 116 | 0.190 |
Why?
|
| Pharmacogenomic Variants | 1 | 2021 | 42 | 0.190 |
Why?
|
| Airway Management | 1 | 2022 | 47 | 0.190 |
Why?
|
| Anesthetics | 1 | 2021 | 53 | 0.190 |
Why?
|
| Placenta Growth Factor | 2 | 2018 | 72 | 0.190 |
Why?
|
| Follistatin-Related Proteins | 1 | 2020 | 6 | 0.180 |
Why?
|
| Workload | 1 | 2021 | 129 | 0.180 |
Why?
|
| Follistatin | 1 | 2020 | 7 | 0.180 |
Why?
|
| Intubation, Intratracheal | 1 | 2022 | 146 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 126 | 0.180 |
Why?
|
| Analgesics | 1 | 2021 | 119 | 0.180 |
Why?
|
| Seasons | 1 | 2021 | 236 | 0.180 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2019 | 8 | 0.170 |
Why?
|
| Incidence | 3 | 2018 | 1593 | 0.170 |
Why?
|
| Transportation of Patients | 1 | 2019 | 32 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 306 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 275 | 0.170 |
Why?
|
| Workflow | 1 | 2019 | 79 | 0.170 |
Why?
|
| Pneumonia, Aspiration | 1 | 2018 | 19 | 0.160 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 8 | 0.160 |
Why?
|
| Neuromuscular Blockade | 1 | 2018 | 26 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2746 | 0.160 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2018 | 29 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 2 | 2016 | 123 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 105 | 0.160 |
Why?
|
| Down-Regulation | 1 | 2020 | 519 | 0.160 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 902 | 0.160 |
Why?
|
| Carrier State | 1 | 1998 | 39 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1998 | 46 | 0.160 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 70 | 0.160 |
Why?
|
| Rats | 2 | 2022 | 4041 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2018 | 84 | 0.160 |
Why?
|
| Oxytocics | 1 | 2018 | 23 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 137 | 0.150 |
Why?
|
| Leukocytosis | 1 | 2017 | 16 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.150 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2017 | 69 | 0.150 |
Why?
|
| Cystectomy | 1 | 2018 | 105 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2018 | 107 | 0.150 |
Why?
|
| Heart Rate | 2 | 2017 | 492 | 0.150 |
Why?
|
| Oxytocin | 1 | 2018 | 72 | 0.150 |
Why?
|
| Maternal Mortality | 1 | 2017 | 15 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 1252 | 0.140 |
Why?
|
| Bradycardia | 1 | 2017 | 39 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 201 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2022 | 361 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 360 | 0.140 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2017 | 152 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.140 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 298 | 0.130 |
Why?
|
| Protamines | 1 | 2015 | 8 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2018 | 705 | 0.130 |
Why?
|
| Hepatitis C | 1 | 1998 | 219 | 0.130 |
Why?
|
| Hemodynamics | 2 | 2018 | 728 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2021 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2017 | 686 | 0.130 |
Why?
|
| Puerperal Disorders | 1 | 2015 | 32 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2012 | 2447 | 0.130 |
Why?
|
| Child | 2 | 2020 | 7094 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 379 | 0.130 |
Why?
|
| Computer Simulation | 4 | 2016 | 1095 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 318 | 0.130 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 235 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 303 | 0.130 |
Why?
|
| Gestational Age | 1 | 2016 | 322 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 947 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 55 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 707 | 0.120 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 43 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2018 | 867 | 0.120 |
Why?
|
| Demography | 1 | 2014 | 181 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2021 | 2290 | 0.120 |
Why?
|
| HIV Infections | 1 | 2002 | 829 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1542 | 0.110 |
Why?
|
| Learning | 1 | 2016 | 283 | 0.110 |
Why?
|
| User-Computer Interface | 2 | 2011 | 187 | 0.110 |
Why?
|
| Neuropeptide Y | 1 | 2012 | 32 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2011 | 177 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2015 | 283 | 0.110 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2012 | 30 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 383 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2012 | 131 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2015 | 269 | 0.100 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2012 | 41 | 0.100 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 50 | 0.100 |
Why?
|
| Animals | 6 | 2024 | 27238 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2012 | 159 | 0.100 |
Why?
|
| Tricuspid Valve Stenosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 161 | 0.100 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2011 | 21 | 0.090 |
Why?
|
| Saphenous Vein | 1 | 2011 | 61 | 0.090 |
Why?
|
| Succinylcholine | 2 | 2022 | 14 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2011 | 55 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 234 | 0.090 |
Why?
|
| Water-Electrolyte Balance | 1 | 2010 | 67 | 0.090 |
Why?
|
| ROC Curve | 1 | 2012 | 773 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 317 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 364 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2024 | 158 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2011 | 261 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2011 | 243 | 0.080 |
Why?
|
| Teaching | 1 | 2010 | 147 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 373 | 0.070 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 144 | 0.060 |
Why?
|
| Chicago | 2 | 2020 | 1411 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2347 | 0.060 |
Why?
|
| Fetal Distress | 1 | 2002 | 7 | 0.050 |
Why?
|
| Perfusion | 1 | 2024 | 230 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 6 | 0.050 |
Why?
|
| Electrocardiography | 2 | 2018 | 495 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2598 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Bupivacaine | 1 | 2022 | 45 | 0.050 |
Why?
|
| Florida | 1 | 2021 | 56 | 0.050 |
Why?
|
| HIV-1 | 1 | 2002 | 164 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.050 |
Why?
|
| Fentanyl | 1 | 2022 | 67 | 0.050 |
Why?
|
| Texas | 1 | 2021 | 109 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2022 | 76 | 0.050 |
Why?
|
| Age Distribution | 1 | 2021 | 200 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2638 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 46 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 1234 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2024 | 1649 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 127 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 109 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 163 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2021 | 160 | 0.050 |
Why?
|
| New York City | 1 | 2020 | 61 | 0.050 |
Why?
|
| Washington | 1 | 2020 | 49 | 0.050 |
Why?
|
| Coronary Angiography | 2 | 2012 | 238 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 30 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 30 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 444 | 0.040 |
Why?
|
| Laboratories | 1 | 2020 | 44 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.040 |
Why?
|
| Pulsatile Flow | 1 | 2019 | 50 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 82 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 401 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 183 | 0.040 |
Why?
|
| Atracurium | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 665 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 466 | 0.040 |
Why?
|
| Colostrum | 1 | 1998 | 2 | 0.040 |
Why?
|
| Milk, Human | 1 | 1998 | 44 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 94 | 0.040 |
Why?
|
| Fetal Blood | 1 | 1998 | 92 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2018 | 27 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1054 | 0.040 |
Why?
|
| Uterus | 1 | 2019 | 221 | 0.040 |
Why?
|
| Therapeutics | 1 | 2017 | 12 | 0.040 |
Why?
|
| Ischemia | 1 | 2019 | 251 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 222 | 0.040 |
Why?
|
| RNA, Viral | 1 | 1998 | 333 | 0.040 |
Why?
|
| Hepacivirus | 1 | 1998 | 165 | 0.040 |
Why?
|
| Perinatal Care | 1 | 2017 | 19 | 0.040 |
Why?
|
| Pneumonia | 1 | 2018 | 183 | 0.040 |
Why?
|
| APACHE | 1 | 2016 | 22 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 195 | 0.040 |
Why?
|
| Software | 2 | 2011 | 663 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 149 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1588 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 889 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 146 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2018 | 269 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 579 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2015 | 38 | 0.030 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 11708 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 40 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 537 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2015 | 90 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 407 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2015 | 91 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 642 | 0.030 |
Why?
|
| Aorta | 1 | 2015 | 286 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 759 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 598 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1945 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 355 | 0.030 |
Why?
|
| Echocardiography, Four-Dimensional | 1 | 2012 | 1 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 230 | 0.030 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2012 | 3 | 0.030 |
Why?
|
| Bromocriptine | 1 | 2012 | 12 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 16 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 388 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 43 | 0.030 |
Why?
|
| Infant | 1 | 1998 | 3121 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 115 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 146 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 141 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 582 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 299 | 0.020 |
Why?
|
| Oxygen | 1 | 2015 | 743 | 0.020 |
Why?
|
| Surgeons | 1 | 2015 | 244 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2011 | 116 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2010 | 100 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2325 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 420 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 238 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 865 | 0.020 |
Why?
|
| Myocardium | 1 | 2012 | 573 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 443 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2012 | 312 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2011 | 299 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 102 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 973 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 605 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 266 | 0.020 |
Why?
|
| Physicians | 1 | 2016 | 684 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1987 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 350 | 0.020 |
Why?
|